Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1

Heba Alshaker(University of East Anglia), Dmitri Pchejetski(University of East Anglia), Mathias Winkler(National Health Service), Torsten Böhler(Charité - Universitätsmedizin Berlin), Yoshiaki Kawano, Qi Wang(Harvard University), Colin Cooper(Institute of Cancer Research), Tawfiq Arafat(Jordan Hospital)
Oncotarget
November 4, 2016
Cited by 36


Related Papers